Literature DB >> 6640400

Postoperative malignant hyperthermia and dantrolene therapy.

U Schulte-Sasse, W Hess, H J Eberlein.   

Abstract

A case of malignant hyperthermia (MH) in a three-year eight-month-old girl is presented. Definite symptoms of MH developed in the awake patient 30 min after termination of anaesthesia which had lasted five hours. This postoperative MH-episode resolved promptly following intravenous administration of dantrolene (2.5 mg X kg-1 initially, followed by 5 mg X kg-1 over 12 hours). Results of serial serum samples revealed a steady increase in creatine kinase (CK) concentration with the highest value being observed at the second day, despite dantrolene therapy. The unusual occurrence of MH in the postoperative period, when the major effects of anaesthesia were no longer an important consideration, is discussed with regard to the "human stress syndrome." The necessity to give this information to people usually not familiar in diagnosing MH (e.g., medical personnel in surgical wards) is stressed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6640400     DOI: 10.1007/BF03015235

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  28 in total

1.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1975-01       Impact factor: 9.166

2.  Beneficial effects of dantrolene sodium in exercise-induced muscle pains: calcium mediated?

Authors:  T Bertorini; G Palmieri; S Bhattacharya
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

3.  Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.

Authors:  P J Halsall; P A Cain; F R Ellis
Journal:  Br J Anaesth       Date:  1979-10       Impact factor: 9.166

4.  Postoperative malignant hyperthermia: a case report.

Authors:  J Beldavs; V Small; D A Cooper; B A Britt
Journal:  Can Anaesth Soc J       Date:  1971-03

5.  Recrudescence after survival of an initial episode of malignant hyperthermia.

Authors:  A Mathieu; A J Bogosian; J F Ryan; R K Crone; D Crocker
Journal:  Anesthesiology       Date:  1979-11       Impact factor: 7.892

6.  Management of suspected malignant hyperpyrexia in an infant.

Authors:  D K Faust; S D Gergis; M D Sokoll
Journal:  Anesth Analg       Date:  1979 Jan-Feb       Impact factor: 5.108

7.  [The inhibitory effect of dantrolene on the rise of serum-creatine-kinase activity after combined use of halothane and suxamethonium in man (author's transl)].

Authors:  J Plötz; J Braun; R Stallenberger
Journal:  Anaesthesist       Date:  1981-07       Impact factor: 1.041

8.  Malignant hyperthermia in a myopathic child. Prolonged postoperative course requiring dantrolene.

Authors:  R Fletcher; G Blennow; A K Olsson; E Ranklev; K Törnebrandt
Journal:  Acta Anaesthesiol Scand       Date:  1982-10       Impact factor: 2.105

9.  Association of post-anaesthetic hyperthermia with abnormal muscle characteristics: a case report.

Authors:  B J Kripke; T J Blanck; D A Sizemore; F L Comunale; J Christiansen; R Gruener
Journal:  Can Anaesth Soc J       Date:  1983-05

10.  [Malignant hyperthermia during the 13th general anaesthesia (author's transl)].

Authors:  K Püschel; I Schubert-Thiele; L Hirth; H G Benkmann; B Brinkmann
Journal:  Anaesthesist       Date:  1978-10       Impact factor: 1.041

View more
  1 in total

Review 1.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.